Target
macrophage inhibitory factor
1 abstract
Abstract
Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM).Org: Department of Neurology, Brigham and Woman’s Hospital, Harvard Medical School, Boston, MA, Cleveland Clinic Lerner Research Institute, Cleveland, OH, MediciNova, La Jolla, CA,